Compare Nike Inc (NKE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nike Inc trades at $42.96 (market cap $64.49B), while State Street SPDR S&P Biotech ETF trades at $154.32. The key difference: Nike Inc pays a 3.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nike Inc nearer its low. Which is the better fit depends on your goals.
| NKE | XBI | |
|---|---|---|
Market Cap | $64.49B | — |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $79.24 | $164.28 |
52-Week Low | $40.75 | $85.16 |
Enterprise Value | $66.49B | — |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
